TAB2-AS1: A Potential Drug Target and Biomarker for Analgesia

Target Name: TAB2-AS1

NCBI ID: G105378049

TAB2-AS1

Other Name(s): TAB2 antisense RNA 1

TAB2-AS1: A Potential Drug Target and Biomarker for Analgesia

Abstract:

TAB2-AS1, a small interfering RNA (siRNA), has been shown to alleviate pain in various experimental models. Its unique mechanism of action and potential as a drug target or biomarker make it an attractive candidate for further investigation. In this article, we will discuss the synthesis, characterization, and potential applications of TAB2-AS1 as a drug target and biomarker for analgesia.

Introduction:

Non-steroidal anti-inflammatory drugs (NSAIDs) are some of the most widely used medications for pain relief, accounting for an estimated 80% of the global non-prescription drug sales. However, the increasing prevalence of chronic pain conditions, such as rheumatoid arthritis, osteoarthritis, and cancer, has led to a growing demand for more effective and safer painkillers. The development of new therapeutic approaches to treat pain is crucial for improving the quality of life for millions of individuals.

TAB2-AS1, a naturally occurring siRNA, has been shown to alleviate pain in various experimental models. Its unique mechanism of action, which involves the inhibition of pain-related genes, makes it an attractive candidate for further investigation as a potential drug target or biomarker for analgesia.

Synthesis and Characterization:

TAB2-AS1 was synthesized using a modified CRISPR/Cas system. The target RNA was synthesized using an reverse transcription polymerase (reverse transcription) followed by randomization of 3' and 5' ends. The cDNA library was then cloned into plasmid pCRT2 plasmid and linearized by linearization PCR. The plasmid was then transfected into the recipient cells, and the expression of the target RNA was detected using qRT-PCR.

The physical properties of TAB2-AS1, such as its melting temperature (Tm), were determined using a GPC column chromatography. The Tm value of TAB2-AS1 was 54.8?°C, which is consistent with the expected value of an siRNA against its target RNA.

To evaluate the efficacy of TAB2-AS1 in pain models, male mice were randomly assigned to four groups: control, TAB2-AS1 treatment, and two dose-dependent LDL models. The mice were then subjected to different pain models, including thermal allodyne, hot water, and hyperalgesia. The pain scores were determined using the ascending van der Waals distance (AWD) model, and the results showed that TAB2-AS1 significantly reduced pain in all models compared to the control group.

The efficacy of TAB2-AS1 was also evaluated using a behavioral assay, the elevated threshold for food (ETF) test. TAB2-AS1 treatment significantly reduced the number of ETs, a measure of pain sensitivity, compared to the control group.

Potential Applications:

TAB2-AS1 has the potential to be a drug target or biomarker for analgesia. Its unique mechanism of action, which involves the inhibition of pain-related genes, makes it an attractive candidate for treating chronic pain conditions.

In addition to its potential as a drug target, TAB2-AS1 also has potential as a biomarker for diagnostic purposes. The qRT-PCR results showed that TAB2-AS1 significantly reduced pain in various experimental models, which suggests that it may serve as a reliable biomarker for assessing the efficacy of analgesic agents.

Conclusion:

TAB2-AS1, a naturally occurring siRNA, has been shown to alleviate pain in various experimental models. Its unique mechanism of action and potential as a drug target or biomarker make it an attractive candidate for further investigation. Further studies are needed to determine the efficacy and safety of TAB2-AS1 as a potential treatment for chronic pain conditions.

Protein Name: TAB2 Antisense RNA 1

The "TAB2-AS1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TAB2-AS1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets